S55746
Based on 1 publication(s) in Google Scholar
S55746 (BCL201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BCL201) has antitumor activity with low toxicity.
For research use only. We do not sell to patients.
- Purity: 99.91%
- CAS No.: 1448584-12-0
- Formula: C43H42N4O6
- Molecular Weight:710.82
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) S55746
More
Biological Activity
|
Bcl-2 1.3 nM (Ki) |
Bcl-xL 520 nM (Ki) |
Bcl-2 3.9 nM (Kd) |
Bcl-xL 186 nM (Kd) |
S55746 (0-1 μM) potently and selectively induces cell death[1].
S55746 selectively induces apoptosis through BCL-2 inhibition in a BAX/BAK-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:H146 and RS4;11 cell lines.
-
Concentration:0, 0.1, 0.3 and 1 μM.
-
Incubation Time:72 hours.
-
Result:Potently induced RS4;11 cell killing after 72 h of treatment with an IC50 of 71.6 nM.
S55746 (20-100 mg/kg, p.o.) inhibits xenograft growth in RS4;11 and Toledo models time- and dose-dependently[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female SCID/beige mice implanted subcutaneously with 3×106 Toledo or RS4;11[1].
-
Dosage:20, 50, 100 mg/kg.
-
Administration:Oral gavage daily for 7 consecutive days.
-
Result:Induced significant anti-tumor activity time- and dose-dependently.
-
Animal Model:SCID/beige female mice with RS4;11 tumor xenografts[1].
-
Dosage:25 and 100 mg/kg.
-
Administration:Single oral gavage treatment.
-
Result:Did not induce platelet loss in vivo at 25 and 100 mg/kg.
Chemical Information
-
CAS No. 1448584-12-0
-
Appearance Solid
-
Molecular Weight 710.82
-
Formula C43H42N4O6
-
Color White to light yellow
-
SMILES
O=C(C1=C2CCCCN2C(C3=C(C(N4CC5=C(C=CC=C5)C[C@H]4CN6CCOCC6)=O)C=C(OCO7)C7=C3)=C1)N(C8=CC=C(O)C=C8)C9=CC=CC=C9
-
Synonyms
BCL201
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Biomed Pharmacother
Foeniculum vulgare seed extract induces apoptosis in lung cancer cells partly through the down-regulation of Bcl-2. [Abstract]2021 Mar:135:111213. PMID: 33395604
Solvent & Solubility
DMSO : 75 mg/mL (105.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 5.75 mg/mL (8.09 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 5.75 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (57.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.52 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4068 mL | 7.0341 mL | 14.0683 mL | 35.1706 mL |
| 5 mM | 0.2814 mL | 1.4068 mL | 2.8137 mL | 7.0341 mL | |
| 10 mM | 0.1407 mL | 0.7034 mL | 1.4068 mL | 3.5171 mL | |
| 15 mM | 0.0938 mL | 0.4689 mL | 0.9379 mL | 2.3447 mL | |
| 20 mM | 0.0703 mL | 0.3517 mL | 0.7034 mL | 1.7585 mL | |
| 25 mM | 0.0563 mL | 0.2814 mL | 0.5627 mL | 1.4068 mL | |
| 30 mM | 0.0469 mL | 0.2345 mL | 0.4689 mL | 1.1724 mL | |
| 40 mM | 0.0352 mL | 0.1759 mL | 0.3517 mL | 0.8793 mL | |
| 50 mM | 0.0281 mL | 0.1407 mL | 0.2814 mL | 0.7034 mL | |
| 60 mM | 0.0234 mL | 0.1172 mL | 0.2345 mL | 0.5862 mL | |
| 80 mM | 0.0176 mL | 0.0879 mL | 0.1759 mL | 0.4396 mL | |
| 100 mM | 0.0141 mL | 0.0703 mL | 0.1407 mL | 0.3517 mL |